Orano USA

Headquartered in Bethesda, Maryland, near the nation's capital, Orano USA is a leading technology and services provider for decommissioning shutdown nuclear energy facilities, used fuel management, federal site clean-up and closure, and the sale of uranium, conversion, and enrichment services to the U.S. commercial and federal markets.

In the nuclear medicine field, Orano Med is developing a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells.

By using this website, you agree with the cookies use. To get more information, manage or modify the cookies parameters on your computer, please read our Cookies Policy in the Legal Notice
Accept cookies